A case report of hepatitis B carriage in a patient with ankylosing spondylitis improving following infliximab treatment and a review of the literature

Journal of Back and Musculoskeletal Rehabilitation

Volumn 20, Issue 2-3, 2007, Pages 123-125

  Capkin, Erhan ^a   Karkucak, Murat ^a   Yilmaz, Gürdal ^a   Aydin, Kemalettin ^a   Tosun, Mehmet ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Ankylosing spondylitis; Anti TNF ; Hepatitis B virus

Indexed keywords

C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HEPATITIS B SURFACE ANTIGEN; HLA B27 ANTIGEN; INFLIXIMAB; LIVER ENZYME; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BACKACHE; CASE REPORT; CLINICAL FEATURE; DISEASE CARRIER; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; JOINT RADIOGRAPHY; LABORATORY TEST; MALE; MUSCLE STIFFNESS; MYALGIA; PHYSIOTHERAPY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SACROILIITIS; SEDIMENTATION RATE;

EID: 39049148024     PISSN: 10538127     EISSN: None     Source Type: Journal    
DOI: 10.3233/BMR-2007-202-310     Document Type: Article

References (20)

1. J. Braun, T. Pham, J. Sieper and J. Davis, International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis, Ann Rheum Dis 62 (2003), 817-824.
2. L.H. Calabrese, N. Zein and D. Vassilopoulos, Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: Hepatitis C, hepatitis B, and HIV infection, Ann Rheum Dis 63 (2004), 18-24.
3. R. de Franchis, A. Hadengue, G. Lau et al., EASL International Consensus Conference on Hepatitis B. 13-14 September 2002, Geneva, Switzerland. Consensus statement (long version), J Hepatol 39 (2003), 3-25.
4. T. Ellerin, R.H. Rubin and M.E. Weinblatt, Infections and anti-tumor necrosis factor alpha therapy, Arthritis Rheum 48 (2003), 3013-3022.
5. L.G. Guidotti, Ishikawa, M.V. Hobbs et al, Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes, Immunity 4 (1996), 25-36.
6. G. Herbein and W.A: O'Brien, Tumour necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis, Proc Soc Exp Biol Med 223 (2000), 24l-257.
7. M. Hochberg, A. Silman, J. Smolen, M. Welmblat and M. Weisman, Rheumatology, Third ed., Mosby, 2003, 1183-1186.
8. S. Kasahara, K. Aado, K, Saito et al., Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus specific cytotoxic T lymphocytes. J Virol 77 (2003), 2469-2476.
9. K.H. Kim and B.L. Seong, Pro-apoptopic function of HBV X protein is mediated by interaction with c-FLIP and enhancement of death-inducing signal, EMBO J 22 (2003), 2104-2116.
10. M. Michel, C. Duvoux, C. Hecode and D. Cherqui, Fulminan hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease, J Rheumatol 30 (2003) 1624-4625.
11. F. Monsalve-De Castillo, T.A. Romero, J. Estevez et al., Concentrations of cytokines, soluble interleukin-2 receptor, and soluble CD30 in sera of patients with hepatitis B virus infection during acute and convalescent phases, Clin Diagn Lab, Immunol 9 (2002), 1372-1375.
12. O. Oniankitan C. Duvoux, D. Challine et al., Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C, J Rheumatol 31 (2004), 107-109.
13. P. Ostuni C. Botsios and L. Punzi, Hepatitis B reactivation in a chronic hepatitis B surfate antigen carrier witk rheumatoid arthritis treated with infliximab and low dose methotrexate, Ann Rheum Dis 62 (2003), 686-687.
14. V. Pasquetto, S. Wieland, S. Uprichard et al., Cytokine-sensitive replication of hepatitis P virus in immortalized Mouse hepatocyte cultures, J Virol 76 (2002), 5646-5653.
15. Safety apdate on TNF-a antagonists: Infliximab and etanercept. Food and Drug Administration, Arthritis Drugs Advisory Committee, 17 August 2001.
16. D. Schluter and M. Deckert, The divergent role of tumor necrosis factor receptors in infectious diseases, Microbes Infect 2 (2000), 1285-1292.
17. F. Su, Schneider RJ Hepatitis B virus HBx protein sensitizes cells to apaptotic killing by tumor necrosis factor alpha, Proc Natl Acad Sci USA 94 (1997), 8744-8749.
18. S. Vento, F. Cainelli and M.S. Longhi, Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: An unresolved issue, Lancet Oncol 3 (2002), 333-340.
19. G.H. Wong and D.V. Goeddel, Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons, Nature 323 (1986), 819-822.
20. K. Yoshioka, S. Kakumu, M. Arao et al., Immunohistochemical studies of intrahepatic tumour necrosis factor alpha in chronic liver disease, J Clin Pathol 43 (1990), 298-302.